Product logins

Find logins to all Clarivate products below.


Key trends to watch:
The race to reinvent weight loss

Learn about how next-generation obesity drugs are changing the obesity treatment landscape.

Next-generation solutions for obesity care

Despite advances with GLP-1 therapies, obesity treatment still faces challenges including side effects and early discontinuation, underscoring the urgent need for continued innovation in this critical area.

Next-generation approaches, including dual and triple hormone receptor agonists, oral formulations, amylin analogs, CB1-targeted drugs and muscle-preserving therapies could deliver safer, more effective and more sustainable care.

Addressing the growing obesity challenge

The prevalence of overweight and obesity is projected to surpass 50% of adults globally by 2030 (World Obesity, 2025). To meet this escalating health crisis, novel therapies are needed that improve outcomes while minimizing side effects and supporting long-term success.

40%
of adults globally are overweight or obese.

(WHO, 2025)
586.7%
increase in GLP-1 prescriptions for overweight or obesity from 2019 to 2024.

(Fair Health, 2025)
$150bn
is the projected value of the global obesity market by 2035.

(Morgan Stanley, 2025)

Emerging obesity drugs

The GLP-1 pipeline is evolving rapidly, and the Drugs to Watch in this category highlight how innovation is continuing to shape obesity care.

Orforglipron
Obesity & T2DM
Retatrutide
Obesity & T2DM